Trial Profile

A Phase 1A/1B Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 With Cyclophosphamide/Fludarabine Lymphodepletion Alone or Including ALLO-647 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALLO 647 (Primary) ; ALLO-316 (Primary) ; Cyclophosphamide; Fludarabine
Indications Renal cell carcinoma
Focus Adverse reactions; First in man; Proof of concept
Acronyms TRAVERSE
Sponsors Allogene Therapeutics

17 Jul 2026 Planned End Date changed from 1 Dec 2025 to 1 Jan 2030.
17 Jul 2026 Planned primary completion date changed from 1 Oct 2025 to 1 Jan 2030.
15 Jul 2026 According to an Allogene Therapeutics media release, results published in the Journal of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com